Loading
Loading
Invoke Bio uses proprietary AI to develop 100% custom immunotherapies for people living with cancer.
Invoke Bio uses proprietary AI to develop 100% custom immunotherapies for people living with cancer. Its machine learning engine integrates multifaceted biomolecular signals and models tumor-immune interaction over time, predicting immunogenic targets with 89% accuracy versus the 10–30% industry standard. The technology is used at Stanford Medicine and UC San Diego Moores Cancer Center, and the company partners with biopharma, diagnostics and research institutions. Backed by Pear VC (PearX Summer 2026), NFX, HCVC and Incite, and a member company of Bakar Bio Labs.
Invoke Bio offers fellows the opportunity to work on AI-driven personalized cancer immunotherapy. Fellows will gain experience with machine learning models that integrate multifaceted biomolecular signals to predict tumor-specific immune targets, with systems deployed in clinical settings including Stanford Medicine and UC San Diego. Backed by Pear VC, NFX, HCVC, and Incite.
Exponential places Spain's most ambitious engineers, designers and founders at startups like Invoke Bio.